SG Americas Securities LLC Acquires 7,339 Shares of Tarsus Pharmaceuticals, Inc. $TARS

SG Americas Securities LLC boosted its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 118.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,518 shares of the company’s stock after acquiring an additional 7,339 shares during the quarter. SG Americas Securities LLC’s holdings in Tarsus Pharmaceuticals were worth $1,107,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Deep Track Capital LP lifted its position in Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock valued at $178,290,000 after acquiring an additional 1,250,000 shares in the last quarter. Jennison Associates LLC lifted its position in Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after acquiring an additional 136,582 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Tarsus Pharmaceuticals by 25.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,247,954 shares of the company’s stock valued at $74,166,000 after acquiring an additional 250,367 shares in the last quarter. Invesco Ltd. lifted its position in Tarsus Pharmaceuticals by 0.9% in the 3rd quarter. Invesco Ltd. now owns 937,006 shares of the company’s stock valued at $55,686,000 after acquiring an additional 8,505 shares in the last quarter. Finally, Artisan Partners Limited Partnership lifted its holdings in shares of Tarsus Pharmaceuticals by 3.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 558,326 shares of the company’s stock valued at $33,181,000 after buying an additional 19,023 shares during the period. 90.01% of the stock is owned by institutional investors.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,231 shares of the stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $283,477.00. Following the completion of the sale, the general counsel owned 63,959 shares in the company, valued at approximately $4,285,253. This represents a 6.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Elizabeth Yeu Lin sold 390 shares of the stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $26,130.00. Following the completion of the sale, the insider owned 23,308 shares of the company’s stock, valued at $1,561,636. The trade was a 1.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 79,391 shares of company stock worth $5,432,035 over the last three months. 8.97% of the stock is currently owned by insiders.

Tarsus Pharmaceuticals Trading Up 4.6%

NASDAQ:TARS opened at $71.89 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 3.82. The firm has a market capitalization of $3.06 billion, a price-to-earnings ratio of -44.38 and a beta of 0.63. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25. The business has a fifty day moving average price of $68.35 and a 200-day moving average price of $71.58.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. Sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Wall Street Zen raised Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, April 4th. Zacks Research cut Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Guggenheim increased their price target on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Oppenheimer increased their price target on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $91.83.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.